Deadly Nanoparcel for Tumors
Nanocage delivery of the azo compound AIPH generates alkyl free radicals that cause DNA damage and lipid and protein peroxidation. Credit: Wiley Press/ Xia Group
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective. Now, American scientists have developed a hybrid nanomaterial that releases a free-radical-generating prodrug inside tumor cells upon thermal activation. As they report in the journal Angewandte Chemie, the free radicals destroy the cell components even in oxygen-depleted conditions, causing apoptosis. Delivery, release, and action of the hybrid material can be precisely controlled.
Many well-established cancer treatment schemes are based on the generation of reactive oxygen species (ROS), which induce apoptosis for the tumor cells. However, this mechanism only works in the presence of oxygen, and hypoxic (oxygen-depleted) regions in the tumor tissue often survive the ROS-based treatment. Therefore, Younan Xia at the Georgia Institute of Technology and Emory University, Atlanta, USA, and his team have developed a strategy to deliver and release a radical-generating prodrug that, upon activation, damages cells by a ROS-type radical mechanism, but without the need for oxygen.
The authors explained that they had to turn to the field of polymerization chemistry to find a compound that produces enough radicals. There, the azo compound AIPH is a well-known polymerization initiator. In medicinal applications, it generates free alkyl radicals that cause DNA damage and lipid and protein peroxidation in cells even under hypoxic conditions. However, the AIPH must be safely delivered to the cells in the tissue. Thus, the scientists used nanocages, the cavities of which were filled with lauric acid, a so-called phase-change material (PCM) that can serve as a carrier for AIPH. Once inside the target tissue, irradiation by a near-infrared laser heats up the nanocages, causing the PCM to melt and triggering the release and decomposition of AIPH.
This concept worked well, as the team has shown with a variety of experiments on different cell types and components. Red blood cells underwent pronounced hemolysis. Lung cancer cells incorporated the nanoparticles and were severely damaged by the triggered release of the radical starter. Actin filaments retracted and condensed following the treatment. And the lung cancer cells showed significant inhibition of their growth rate, independently of the oxygen concentration.
Although the authors admit that "the efficacy still needs to be improved by optimizing the components and conditions involved," they have demonstrated the effectiveness of their hybrid system in killing cells, also in places where the oxygen level is low. This strategy might be highly relevant in nanomedicine, cancer theranostics, and in all applications where targeted delivery and controlled release with superb spatial/temporal resolutions is desired.
Shen, S., Zhu, C., Huo, D., Yang, M., Xue, J. and Xia, Y. (2017). A Hybrid Nanomaterial for the Controlled Generation of Free Radicals and Oxidative Destruction of Hypoxic Cancer Cells. Angewandte Chemie International Edition.
This article has been republished from materials provided by Wiley . Note: material may have been edited for length and content. For further information, please contact the cited source.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE